presentation

N. J. Nandini Carnatic Vocal at Kalakshetra Foundation, Thiruvanmiyur, ECR. | Photo Credit: KARUNAKARAN M N.J. Nandini’s struck a confident note at the Kalakshetra Foundation’s Sunaadam music festival held recently at the aesthetically…

Fetal presentation before birth The way a baby is positioned in the uterus just before birth can have a big effect on labor and delivery. This positioning is called fetal presentation. Babies twist, stretch and tumble quite a…

This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content.…

HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors,…

Nashville, June 29, 2023 (GLOBE NEWSWIRE) -- Ovation® Fertility scientists contributed to four pieces of research accepted for poster presentation at the ESHRE virtual 39th Annual Meeting. The event, hosted by the European Society of…

A good day in the history of video game preservation Remember the Nintendo Dolphin? The N64 successor that would destroy the PlayStation 2 and put Nintendo back on top? Well, Nintendo ended up naming it GameCube, and it fell a bit short of…

Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development, anticipated to resume clinical study in 2H 2023…

IRVINE, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic…

Preclinical data on UCART20x22, Cellectis’ first allogeneic dual CAR T-cell product candidate to treat B-NHL, presented at an oral session Encouraging data presented on gene editing process using Cellectis TALEN® technology to develop…

Des données précliniques sur UCART20x22, le premier produit candidat CAR T allogénique ciblant deux antigènes, développé par Cellectis pour traiter le lymphome non Hodgkinien à cellules B, ont été présentées lors d'une session orale Des…